Loading company…
TrojanBio develops therapeutic antibodies for cancer treatment.
TrojanBio is a preclinical immunotherapy company developing antibodies that combine cancer targeting with viral immunity activation. Its pipeline includes candidates for colon cancer and triple-negative breast cancer. Founded in 2021, the company is based in Ness Ziona, Israel, and was at the Seed stage. In January 2022, it raised pre-seed funding from NFX.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in